What did @jeff.delaney5 actually say?
Jeff described gonadorelin as "a gonadic trope in releasing hormone" used mostly over the last five to ten years in the hormone replacement space. He said it's "somewhat similar to HCG" and can be used to increase natural testosterone, support fertility, or help men on TRT "keep some testicular function." The core message is reasonable, but there are some accuracy issues worth unpacking.
First, the mispronunciation is worth noting because it signals something: the creator says "ganadarillin" throughout, which suggests this may be a topic he knows broadly but hasn't studied in depth. That matters when we're evaluating precision. He also says "ECG" when he clearly means HCG (human chorionic gonadotropin). Small verbal slip or not, comparing these two compounds requires more nuance than a single sentence.
Does the science back this up?
Mostly, yes, with important caveats. Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH). It stimulates the pituitary to release LH and FSH, which in turn signal the testes to produce testosterone and support spermatogenesis. That mechanism is well-established.
A 2023 review by Samplaski et al. in Fertility and Sterility confirmed that GnRH analogs, including gonadorelin, can preserve testicular function in men on exogenous testosterone. Earlier work by Liu et al. (2002, Journal of Clinical Endocrinology and Metabolism) showed that pulsatile GnRH administration successfully restored spermatogenesis in men with hypogonadotropic hypogonadism. The fertility angle is real, but context matters: gonadorelin works best in men whose pituitary-hypothalamic axis is functional. It does not work the same way in all cases of hypogonadism.
The claim that it can "increase the natural testosterone level" is accurate in specific populations, but it is not a general testosterone booster. That framing is too loose.
What did they get wrong (or right)?
The HCG comparison is the shakiest part. HCG mimics LH directly at the testicular level, bypassing the pituitary entirely. Gonadorelin works upstream, stimulating the pituitary first. These are not the same mechanism, and calling them "somewhat similar" glosses over a clinically meaningful difference. For men with pituitary dysfunction, gonadorelin may not work where HCG would.
What he got right: the use case for TRT patients is accurate. When men use exogenous testosterone, LH and FSH suppression leads to testicular atrophy and reduced sperm production. Gonadorelin can interrupt that suppression by keeping the hypothalamic-pituitary-gonadal axis active. That is supported by clinical evidence, including data cited in Ramasamy et al. (2014, The Journal of Urology) on fertility preservation in men undergoing testosterone therapy.
He did not overclaim a cure, did not mention dosing, and did not recommend any stack. That restraint is worth acknowledging.
What should you actually know?
Gonadorelin is not a testosterone booster in the casual sense. It is a prescription peptide that works through a specific hormonal pathway, and its effectiveness depends heavily on whether your pituitary is responding normally. If you have secondary hypogonadism (the pituitary is the problem), it may help. If you have primary hypogonadism (the testes are the problem), it will not.
Compounded gonadorelin, which is what most telehealth platforms dispense, is not the same as branded GnRH products. Formulation, stability, and delivery method vary. The FDA has raised concerns about the compounding of certain peptides, and gonadorelin has faced regulatory scrutiny. Anyone considering it should have a thorough conversation with a licensed provider, not a TikTok video.
Finally, the five-to-ten year timeline Jeff mentions is roughly accurate for mainstream adoption in the TRT optimization space, but gonadorelin itself has been studied for decades in reproductive endocrinology. The "new" framing undersells how much we actually know about it.